|Revision ID||Type||Time Submitted||Versioning Comment|
|2||Therapy||01/27/2017 9:18 PM||Initial version | BCL2 | amplification|
|Variant(s)||BCL2 copy number gain|
|Tumor(s)||Diffuse Large B Cell Lymphoma|
BCL2 genomic Amplification may be associated with sensitivity to BCL2 inhibitors, however these inhibitors are currently undergoing clinical trials and their efficacy and/or lack of toxicity has not yet been demonstrated.
Kendrick SL, et al. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol 2014;45(10):2144-53
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.